Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company

posted Dec 22, 2024 9:00am  by  Voyageur Pharmaceuticals Ltd
Voyageur is securing supply chains in North America for barium, iodine and fullerene drug development and is aiming to gain efficiencies in production of contrast media products. The company anticipates this LOI will expand Voyageur’s project portfolio and diversify the Company’s product mix. The global contrast media market is valued at $6.3 billion with GE HealthCare projecting it will double over the next decade. ...read more